Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer

[1]  F. Xiang,et al.  Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins , 2018, Artificial cells, nanomedicine, and biotechnology.

[2]  Longhuo Wu,et al.  Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets , 2018, Cellular Physiology and Biochemistry.

[3]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[4]  F. Cheng,et al.  Inhibition of histone deacetylases sensitizes EGF receptor‐TK inhibitor‐resistant non‐small‐cell lung cancer cells to erlotinib in vitro and in vivo , 2017, British journal of pharmacology.

[5]  W. Guo,et al.  Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity , 2017, Cell Death & Disease.

[6]  K. To,et al.  Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. , 2017, Lung cancer.

[7]  X. Roca,et al.  Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer , 2016, Clinical Cancer Research.

[8]  A. Ray,et al.  Biological characteristics of CCN proteins in tumor development. , 2016, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[9]  N. Colabufo,et al.  Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4'-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. , 2016, Journal of medicinal chemistry.

[10]  Ying Wang,et al.  HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. , 2016, Oncology reports.

[11]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[12]  G. Giannini,et al.  Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity. , 2016, European journal of medicinal chemistry.

[13]  Chunfu Wu,et al.  Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo. , 2016, Chemico-biological interactions.

[14]  D. Fennell,et al.  Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. , 2016, Cancer treatment reviews.

[15]  M. Li,et al.  Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms , 2016, Cell Death and Disease.

[16]  Eric S Kim.  Chemotherapy Resistance in Lung Cancer. , 2016, Advances in experimental medicine and biology.

[17]  Cheng Huang,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. , 2016, Cancer letters.

[18]  S. Milstien,et al.  The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer , 2015, Oncogenesis.

[19]  Xing Wang,et al.  Effects of ornithine decarboxylase antizyme 1 on the proliferation and differentiation of human oral cancer cells. , 2014, International journal of molecular medicine.

[20]  R. Poole.  Belinostat: First Global Approval , 2014, Drugs.

[21]  X. Zou,et al.  Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. , 2014, Cancer letters.

[22]  N. Bowden.  Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? , 2014, Cancer letters.

[23]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[24]  D. Stewart,et al.  Review Wnt Signaling Pathway in Non–small Cell Lung Cancer Overview of the Wnt Canonical (β-catenin) and Noncanonical Signaling Pathways , 2022 .

[25]  Wenling Zheng,et al.  Assay of OAZ1 mRNA Levels in Chronic Myeloid Leukemia Combined with Application of Leukemia PCR Array Identified Relevant Gene Changes Affected by Antizyme , 2013, Acta Haematologica.

[26]  D. Richardson,et al.  P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration* , 2013, The Journal of Biological Chemistry.

[27]  C. Robinson,et al.  Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates , 2013, Molecular cell.

[28]  R. Lahue,et al.  Histone deacetylase complexes as caretakers of genome stability , 2012, Epigenetics.

[29]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[30]  J. Pastorek,et al.  P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[31]  R. Dohmen,et al.  Polyamine sensing by nascent ornithine decarboxylase antizyme stimulates decoding of its mRNA , 2011, Nature.

[32]  M. Maitland,et al.  Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Safaei.  Role of copper transporters in the uptake and efflux of platinum containing drugs. , 2006, Cancer letters.

[34]  D. Harpole,et al.  The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[36]  A. Aveni.  Archaeoastronomy in the Maya Region: A Review of the Past Decade , 1981 .